Patents by Inventor Eric Wakshull
Eric Wakshull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11686734Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).Type: GrantFiled: July 7, 2020Date of Patent: June 27, 2023Assignee: BIOGEN MA INC.Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20210025900Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).Type: ApplicationFiled: July 7, 2020Publication date: January 28, 2021Inventors: Meena Subramanyam, Lakshimi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Patent number: 10705095Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).Type: GrantFiled: June 7, 2017Date of Patent: July 7, 2020Assignee: BIOGEN MA INC.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20180088127Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).Type: ApplicationFiled: June 7, 2017Publication date: March 29, 2018Applicant: Biogen MA Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Patent number: 9709575Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.Type: GrantFiled: July 14, 2014Date of Patent: July 18, 2017Assignee: Biogen MA Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20150071917Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: ApplicationFiled: July 14, 2014Publication date: March 12, 2015Applicant: Biogen Idec MA Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Patent number: 8871449Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: GrantFiled: September 23, 2011Date of Patent: October 28, 2014Assignee: Biogen Idec MA Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20120195884Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: ApplicationFiled: September 23, 2011Publication date: August 2, 2012Applicants: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
-
Patent number: 8124350Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: GrantFiled: April 4, 2006Date of Patent: February 28, 2012Assignees: Biogen Idec MA Inc., Elan Pharmaceuticals, Inc.Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin Mcdaid Barbour, Julie Elizabeth Taylor
-
Publication number: 20090176256Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.Type: ApplicationFiled: April 4, 2006Publication date: July 9, 2009Inventors: Meena Subramanyam, Lakshmi Amaravadi, Eric Wakshull, Frances Lynn, Michael Panzara, Robin McDaid Barbour, Julie Elizabeth Taylor
-
Patent number: 6630310Abstract: A preparation containing a receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble &bgr;(1-3)-glucan on activation of signal transduction pathways and agents identified thereby, as well as assays for assessing the specificity of carbohydrate:glycolipid interactions.Type: GrantFiled: October 30, 1998Date of Patent: October 7, 2003Assignee: Biopolymer Engineering Pharmaceutical, Inc.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
-
Patent number: 6110692Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.Type: GrantFiled: January 31, 1997Date of Patent: August 29, 2000Assignee: The Collaborative Group, Ltd.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
-
Patent number: 6090938Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.Type: GrantFiled: June 14, 1996Date of Patent: July 18, 2000Assignee: Collaborative Group, Ltd.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman